Delayed immune-mediated adverse effects of polyalkylimide dermal fillers: Clinical findings and long-term follow-up

Archives of Dermatology

Volumn 144, Issue 5, 2008, Pages 637-642

  Alijotas Reig, Jaume ^a,b,e   Garcia Gimenez, Victor ^c,d   Miró Mur, Francesc ^a   Vilardell Tarrés, Miquel ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Europa Medical Centre   (Spain)

^d SEMFYC International Section   (Spain)

^e NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; AMOXICILLIN; AZITHROMYCIN; CETIRIZINE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; FILLER; HYALURONIC ACID; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; MINOCYCLINE; POLYALKYLIMIDE DERMAL FILLER; PREDNISONE; SILICONE;

ARTICLE; BLOOD EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; FOLLOW UP; GRANULOMA; HUMAN; IMPLANT; LATENT PERIOD; MALE; PRIORITY JOURNAL; SKIN ALLERGY; SKIN BIOPSY; THORAX RADIOGRAPHY;

EDEMA; FEMALE; FOLLOW-UP STUDIES; GRANULOMA; HUMANS; INFLAMMATION; MALE; POLYAMINES; PROSPECTIVE STUDIES; PROSTHESES AND IMPLANTS; RECURRENCE; SKIN DISEASES; TIME FACTORS;

EID: 44249094171     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.5.637     Document Type: Article

References (38)

1. De Boulle K. Management of complications after implantation of fillers. J Cosmet Dermatol. 2004;3(1):2-15.
2. Ellis DA, Makdessian AS, Brown DJ. Survey of future injectables. Facial Plast Surg Clin North Am. 2001;9(3):405-411.
3. Frank PJ. Cosmetic symposium: Restylane. Dermatologic Society of Greater New York Web site. Http://www.dersociety.org/default.asp?id=3&aui= sa&aid=35. Accessed February 2, 2005.
4. Engelman DE, Bradley B, Glodberg DJ. Dermal fillers: complications and informed consent. J Cosmet Laser Ther. 2005;7(1):29-32.
5. Andre P, Lowe NJ, Parc A, Clerici TH, Zimmermann U. Adverse reactions to dermal fillers: a review of European experiences. J Cosmet Laser Ther. 2005;7(3-4):171-176.
6. Duffy DM. Complications of fillers: overview. Dermatol Surg. 2005;31(11, pt 2):1626-1633.
7. Bergeret-Galley C. Comparison of resorbable soft-tissue fillers. Aesthetic Surg J. 2004;24(January/February):33-46.
8. Polymekon. Bio-Alcamid, the injectable prosthesis. In: Polymekon, ed. Material Reserved for Physicians. Brindisi, Italy: Polymekon Research; 2003:1-13.
9. Pacini S, Ruggiero M, Cammarota N, Protopapa C, Gulisano M. Bio-Alcamid: a novel prosthetic polymer, does not interfere with morphological and functional characteristics of human skin fibroblasts. Plast Reconstr Surg. 2003;111(1):489-491.
10. Pacini S, Ruggiero M, Morucci G, Cammarota N, Protopapa C, Gulisano M. Bio-Alcamid: a novelty for reconstructive and cosmetic surgery. Ital J Anat Embryol. 2002;107(3):209-214.
11. Ramires PA, Miccoli MA, Panzarini E, Dini L, Proptopapa C. In vitro and in vivo biocompatibility evaluation of polyalkylimide hydrogel for soft tissue augmentation. J Biomed Mater Res B Appl Biomater. 2005;72(2):230-238.
12. Claoue BL, Rabineau P. The polyalkylimide gel: experience with Bio-Alcamid. Semin Cutan Med Surg. 2004;23(4):236-240.
13. Protopapa C, Sito G, Caporale D, Cammarota N. Bio-Alcamid in drug-induced lipodystrophy. J Cosmet Laser Ther. 2003;5(3-4):226-230.
14. Karim RB, Hage JJ, van Rozelaar L, Lange CAH, Raajimakers J. Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases. J Plast Reconstr Aesthet Surg. 2006;59(12):1409-1414.
15. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for tissue augmentation. Aesthetic Plast Surg. 2003;27(5):354-366.
16. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-560.
17. Chung RT, Podolsky DK. Cirrhosis and its complications. In: Kasper DL, Fauci AS, Longo AL, et al, eds. Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill; 2005:1858-1869.
18. Miyoshi K, Shiragani H, Yoshida K. Adjuvant disease of man. Clin Immunol (Tokyo). 1973;5:785-794.
19. Christensen L, Breiting V, Janssen M, Vuust J, Hogdall E. Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg. 2005;29(1):34-48.
20. Bui P, Pons-Guiraud A, Kuffer R, Plantier F, Nicolau P. Slowly absorbable and non absorbable injectable products [in French]. Ann Chir Plast Esthet. 2004;49(5):486-502.
21. Requena C, Izquierdo MJ, Navarro M, Martinez A, Vilata JJ, Botella R. Adverse reactions to injectable aesthetic microimplants. Am J Dermatopathol. 2001;23(3):197-202.
22. Treacy PJ, Goldberg DJ. Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs. Dermatol Surg. 2006;32(6):804-808.
23. R), high-volume filling material for facial reconstruction in patients with HIV-related facial lipodystrophy: presentation of 100 cases. Dermatologia CMQ. 2004;2(2):1-5.
24. Treacy PJ, Goldberg DJ. Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs. Dermatol Surg. 2006;32(6):804-808.
25. Gell PG, Coombs RR, eds. Clinical Aspects of Immunology. Oxford, England: Blackwell; 1963.
26. James DG, Williams WJ. Sarcoidosis and Other Granulomatous Disorders. Philadelphia, PA: WB Saunders Co; 1985. Major Problems in Internal Medicine; vol 24.
27. Antonovich DD, Callen J. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol. 2005;141(7):869-872.
28. Dal Sacco D, Cozzani E, Parodi A, Rebora A. Scar sarcoidosis alter hyaluronic acid injection. Int J Dermatol. 2005;44(5):411-412.
29. Alijotas-Reig J, Garcia-Gimenez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long term follow-up and review of the literature. J Eur Acad Dermatol Venereol. 2008;22(2):150-161.
30. Passy S. Implantes de polimetacrilato: un nuevo método para corregir defectos corporales sin cirugía. Int J Cosmetic Med Surg (Ed Esp). 2002;4(1):23-27.
31. Lemperle G, Kind P. Biocompatibility of Artecoll. Plast Reconstr Surg. 1999;103(1):338-340.
32. Filion MC, Phillips NC. Pro-inflammatory activity of contaminating DNA in hyaluronic acid preparations. J Pharm Pharmacol. 2001;53(4):555-561.
33. Christen U, von Herrath G. Infections and autoimmunity: good or bad? J Immunol. 2005;174(12):7481-7486.
34. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-1533.
35. Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004;351(21):2203-2217.
36. Rynes RI. Antimalarial drugs. In: Kelley WN, Harris ED, Ruddyn S, Sledge CB, eds. Textbook of Rheumatology. 4th ed. Philadelphia, PA: WB Saunders; 1993:731-742.
37. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine level in systemic lupus erythematosus patients. Lupus. 2006;15(5):268-275.
38. Vedamurthy M. Soft tissue augmentation: use of hyaluronic acid as dermal filler. Indian J Dermatol Venereol Leprol. 2004;70(6):383-387.